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Since 1981, when the liver transplantation program 
was initiated at the University of Pittsburgh, we have 
been impressed with the prevalence of pancreatitis oc-
curring following liver transplantation in patients 
transplanted for hepatitis B-related liver disease. To 
either confirm this clinical impression or refute it, the 
records of the 27 HbsAg"" patients and those of an addi-
tional 24 HbsAg- but HbcAb and/or HbsAb+ patients 
who underwent orthotopic liver transplantation were 
reviewed to determine the prevalence of clinical pan-
creatitis and hyperamylasemia (biochemical pancreati-
tis) following liver transplantation (OLTx). Post-OLTx 
hyperamylasemia occurred significantly more fre-
quently in HbsAg+ patients (6/27) than it did in the 
HbsAg- patients (0/24) (P<0.05). More importantly, 
clinical pancreatitis occurred in 14% (4/27) of the 
HbsAg+ patients and 0% (0/24) of the HbsAg- patients. 
Interestingly, in each case, the pancreatitis was associ-
ated with the occurrence of acute hepatitis B infection 
of the allograft. 
Based upon these data., we conclude that pancreatitis 
occurring after liver transplantation is more common in 
patients transplanted for active viral liver disease 
caused by hepatitis B than in those with inacth .. e viral 
liver disease. These observations suggest that pancrea-
titis occurring in, at least some cases following liver 
transplantation for viral liver disease, may result from 
hepatitis B virus infection of the pancreas. 
The frequency of pancreatitis following renal transplantation 
has been reponed to vary between 0.4 % and 7% and to be 
associated with a mortality between 20-70% (1-6). Mecha-
nisms proposed as putative causes for the pancreatitis include: 
the immunosuppressive medications utilized especially gluco-
corticoids and/or azathioprine, unidentified viral infections, 
postoperative hyperparathyroidism, vasculitis, and intraopera-
tive pancreatic trauma. Since 1981 when the liver transplan-
tation program was initiated at the University of Pittsburgh, 
pancreatitis has been obsel\-ed occasionally in liver allograft 
recipients. Its occurrence in HbsAg+ patients with postopera-
tive hepatitis B infection of the allograft has been particularly 
impressive. To evaluate this possible association, a retrospec-
tive analysis of the incidence of post·orthotopic liver transplan-
tation (OLTx)* pancreatitis ill HbsAg+ patients compared with 
that found in a control group of HbsAg- patients with labora-
tory evidence of prior hepatitis B exposure was performed. The 
results of this study are reported here. 
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* Abbreviation used: OL Tx, orthotopic liver transplantation. 
MATERIALS AND METHODS 
Subjects. All of the in'patient and out-patient records of the 2'7 
HbsAg + patients who underwent orthotopic liver transplantation at 
the Presbyterian University Hospital of the University of Pittsburgh 
Health Science Center between January 1st, 1981 and December 31st. 
1986 were reviewed. Twenty-four of these 27 patients (89%) underwent 
OL Tx for advanced cirrhosis with chronic hepatic insufficiency, while 
three (11 %) were transplanted for hepatocellular carcinoma with clin-
ically stable cirrhosis. The records of 24 patients who had serologic 
evidence of prior hepatitis B infection, and who underwent OL Tx 
during the same time period, were reviewed as a control population. 
Each of these latter 24 patients was HbsAg- and was HbcAb+ and/or 
HbsAb+, and had not been immunized with a pancreatitis B virus 
vaccine. Nineteen of these 24 patients had OLTx for advanced post-
necrotic cirrhosis with chronic hepatic insufficiency, and five (19%) 
underwent the procedure because of hepatocellular carcinoma in an 
indi .. ;dual with stable cirrhosis. Table 1 demonstrates the historical, 
clinical, and laboratory data available on these two groups of liver 
transplant recipients. The follow-up data are to May 31st, 1987. 
Clinical evaluation. The presence or absence and degree of hepatic 
encephalopathy in each subject prior to OLTx was determined clinically 
as well as prospectively by hepatology fellows using established criteria 
and was scored from 0-2 as follows (7): 
Grade 0: No clinically evident encephalopathy 
Grade 1: Clinical stage 1-2 encephalopathy. 
Grade 2: Clinical stage 3-4 encephalopathy 
Similarly, the presence or absence of ascites prior to OL Tx was 
scored prospectively by hepatology fellows on a scale running from 0-
2 as follows: 
Grade 0: No ascites evident by ultrasonography 
Grade 1: Mild-to·moderate amount of ascites responsive to diuretic 
therapy 
Grade 2: A large volume of ascites poorly controlled by diuretic 
therapy 
Finally, the patients' functional status immediately prior to OL Tx 
was also scored prospectively on a scale ranging from 0-3 as follows: 
Grade 0: Living at home and working 
Grade 1: Living at home but unable to work due to hepatic disease 
Grade 2: Hospitalized 
Grade 3: Hospitalized in an intensive care unit 
Dio6nostic testiTJI. All preoperative laboratory and diagnostic tests 
were performed according to an established protocol. Posttransplan-
tation data were obtained as clinically indicated. Amylase determina-
tions are routinely made on all patients with abdominal pain and at 
the time of each readmission regardless of the presenting complaints 
or physical findings. No laboratory or diapostic testing for the sole 
purpoee of this investigation was performed. Serum amylase measure· 
ments _re performed by the clinical pathology department of Pres-
byterian University Hospital using the Kodak Enzymatic Amylase Kit, 
which \BeS paranitrophenol maltopentaoside as the substrate (Eastman 
Kodak Co., Rochester, NY). 
All of the pathologic specimens reported here were examined by a 
single pathologist skilled in the interpretation of liver transplantation 
and pancreatitis B liver histopathology. 
Definition of pancreatitis. For the purpose of this investigation "pan· 
creatitis- was defined as an elevation of the llerum amylase to a level 
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,reater than twice the upper limit of the normal range in usociation 
"nth radiographic and/or clinical symptomatology suggesting pancrea-
titia-specifically abdominal pain with or without nausea and/or vom-
itinl. Elevations of the serum amylase to levels greater than twice the 
normal value but without radiologic or clinical evidence consistent with 
pancreatitis was derlDed as hyperamylasemia or biochemical pancrea-
titis. 
SUJtisticol analysis. Statistical analysis wu performed using the 
Students' t test for umpaired samples. Chi-square methods were ueed 
to evaluate the association, as well as differences in proportions; the 
Yates' correction for continuity was incorporated when appropriate. A 
P value leu than 0.05 was considered to be aignificant. 
RESULTS 
There was no differeoce between the HbsAg+ group and the 
HbsAg- group with respect to the percentage of patients 
undergoing OL Tx in each year of the investigation (Table 2). 
There was no difference in the patient SUl'Vival rate between 
the HbsAg+ and HbsAg- groups (data not reported). 
The prevalence of pancreatitis in the HbsAg+ group (4/27) 
was arithmetically but not significantly greater than the prev-
alence in the HbsAg- group (0-24). However, the prevalence of 
pancreatitis plus hyperamylasemia in the HbsAg+ group (6/27) 
TABLE 1. Patient data 
HBsAg(+) HBsAg(-) 
(n-27) (0-24) 
Age 43.0 ± 2.a- 4O.1±3.1 
% Male 89% (24/27)· 58% (14/24) 
A8citea IICOle (0-2) 1.5±0.2b 1.0±0.2 
Encephalopathy score (0- 1.2±O.2 1.l±O.2 
2) 
Status (0-3) 2.O±O.2b 1.5±O.1 
History of variceal bleeding 44% (12/27) 38% (9/24) 
.lJbumin (g,ldl) 2.7±O.1 2.8±O.1 
Prothrombin time (sec 16.3±0.6 16.0±0.5 
[Control- 11.7)) 
Absolute lymphocyte count 1057±132 963±129 
(cells/mm') 
Creatinine (mgfdl) 1.4±O.2 1.0±0.1 
Bilirubin (mg,ldl) 10.5±2.8 7.2±2.1 
° Mean±SEM. 
• P<0.05. 
was statistically greater than in the HbsAg- group (0/24) 
(P<0.05). 
Six patients in the HbsAg+ group were readmitted to Pres-
byterian University Hospital with acute hepatitis B infection 
of the allograft with jaundice. Four of these also had clinical 
pancreatitis. Interestingly, among patients transplanted for 
HbsAg+ disease, post·OL Tx pancreatitis occurred more fre-
quently in those who manifested • picture of clinical acute 
hepatitis B virus infection of the allograft (./6) than in those 
without clinically evident hepatitis B infection in the allograft 
(0/21) (P<O.Ol). Shown in Table 3 are the clinical data on the 
• patients with pancreatitis and two of the patients with 
hyperamylasemia. 
DISCUSSION 
The HbsAg+ study group and the HbsAg- but HbcAb+ or 
HbsAb+ control group were reasonably similar with respect to 
the historical, clinical, and laboratory data assessed and re-
ported in Table 1. However, the HbsAg+ group had a greater 
percentage of male patients (P<O.02), a greater ascites score 
(P<.05), and a poorer performance status score (P<O.05) than 
did the HbsAg- group. The differences in performance status 
and ascites scores between the two IJ'OUPS document the poorer 
clinical condition of the HbsAg+ patients with respect to the 
HbsAg- at the time of transplantation. Despite these differ-
ences, there was no difference in survival between the two 
groups. Since the percentage of patients undergoing OLTx in 
each year of the study was 'similar for both groups, the duration 
of survival was also similar for both groups. 
Three of the four cases of pancreatitis had clinical, laboratory 
and radiolOgic evidence for acute pancreatic inflammatory dis-
TABLE 2. Distribution of OL Tx procedures performed yearly 
Year 
1981 
1982 
1983 
1984 
1985 
1986 
8BaAc(+) 
(n-27) 
0% (0/27) 
11% (3/27) 
4% (1/27) 
11% (3/27) 
22% (6/27) 
52% (14/27) 
0% (0/24) 
17% (4/24) 
0% (0/24) 
13% (3/24) 
13% (3/24) 
58% (14/24) 
TABLE 3. Clinical data on the four cases with pancreatitis and two cases with hyperamylasemia 
Onaetof 
Hepatitis OLTx p8lICreatitis Liver biopsy Amylase cr/80nocr&phic 
statu. date poattrarulplantatioo (IUIL) &ndinp Cae No. Coone 
(cia,.) 
1 HBsAg+ 2-16-82 122 Chronic viral 360 Edematous Died 
HBeAg+ hepatitis pmlCft&B 
2 HBsAg+ 5-11-85 220 Acute viral 325 Unremarkable Alive 
HBeAg+ hepatitis 
3 HBsAg+ 5-31-85 192 Acute viral 497 Pmcreatitis Alive 
HBeAg+ hepatitis 
4 HBsAg+ 6-5-86 103 Acute viral 377 Paacreatic Died 
HBeAg+ hepatitis pbJegmon 
mdpseudo-
~ 
5 HBsAg+ 11-4-86 7S Not done 546 Not done Died 
HBeAc+ 
6 HBsAg+ 11-15-86 20 Not done 560 Not done Alive 
HBeAg+ 
, 
i ~~ 
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ease. The fourth case of pancreatitis had only laboratory and 
clinical evidence highly suggestive of acute pancreatitis. Ele-
vations of the serum amylase value in patients with nonpan-
creatic abdominal pain are certainly well recognized (8-11). 
However, in two large studies in patients with abdominal pain 
and serum amylase values greater than twice the upper normal 
limit were found to be quite specific for pancreatitis (12, 13); 
in the most recent study, an elevated amylase (>2x ULN) had 
specificities of 98.4% and 100% when determined and calcu-
lated using two assay techniques. Patients 5 and 6 had eleva-
tions of the serum amylase to levels similar to those of cases 
1-4 and may have represented subclinical pancreatitis-but, 
because of the lack of symptoms or radiologic evidence of 
pancreatitis, they can only be classified as having hyperamy-
lasemia. Nonetheless, we have observed three definite, one 
highly probable, and two possible cases of pancreatitis in the 
27 individuals in the HbsAg+ group-the one probable and 
three definite cases occurred in association with acute recurrent 
hepatitis B infection of the allograft_ Over the same period, we 
observed no cases of pancre8titis or hyperamylasemia in the 
HbsAg- control group of patients studied. Based upon this 
experience, we conclude that there is greater risk of post-OLTx 
pancreatitis in HbsAg+ patients than there is in HbsAg- pa-
tients, and that pancreatitis is often associated with recurrent 
acute B virus hepatitis of the allograft. 
There are many other possible causes for the observed cases 
of pancreatitis. Postoperative pancre8titis can occur with any 
intraabdominal operation -and, one might expect, with the 
magnitude of dissection required for liver transplantation, to 
observe postoperative pancreatitis not infrequently following 
liver transplantation. With the exception of the hyperamylas-
emia seen in case 6 all of our cases occurred at greater than 
two months post-OL Tx, making postoperative pancreatitis re-
sulting from intraoperative pancreatic trauma an unlikely cause 
of the pancreatitis observed in this investigation (14). Moreover 
operative trauma does not explain the occurrence of pancrea-
titis in HbsAg+ patients and its absence in HbsAb+ patients. 
All post-OLTx patients are on multiple medications, several of 
which are well known to be associated with pancreatitis. All 
post-OL Tx patients receive large doses of corticosteroids and 
most also receive intermittent treatment with furosemide, two 
drugs known to cause pancreatitis (15-21). The use of azathi-
oprine has been associated with pancreatitis as well (22-25). 
Of the six cases herein reported, only patient 5, who developed 
hyperamylasemia, was actively taking or had ever taken azathi-
oprine. The other medications potentially responsible for pan-
creatitis in this series were used equally by both groups_ 
Infectious pancreatitis is well known to occur with the 
mumps virus and has been reported in association with other 
viral and/or parasitic infections, such as Mycoplasma pneuTTW-
nioe, Coxsackie B and ECHO virus (26-29), and a variety of 
fungal and Ascaris lumbricoides (30)_ None of the patients 
herein reported had evidence of a systemic infecti4n, though 
infectious pancreatitis is always an etiologic possibility in any 
patient on immunosuppressive medication. 
Each of the above-identified causes is a possible explanation 
for the development of post-OLTx pancreatitis in the cases we 
report. However, none explains the strikingly different preva-
lence of pancreatitis between the HbsAg+ and HbsAg- groups 
or the 67% prevalence of pancreatitis in transplant patients 
who had "recurrent" acute hepatitis B infection. Pancreatitis 
caused by hepatic necrosis and pancreatitis caused by hepatitis 
B pancreatic infection are more likely causes of the pancreatitis 
observed in this study, as they explain the observed close 
relationship of pancreatitis and recurrent hepatitis B infection. 
An association between pancreatitis and hepatic failure is well 
recognized also. (31-34). In these reports, acute pancreatitis is 
seen most commonly in association with viral hepatitis, but it 
has been reported to occur with other forms of hepatic failure 
as well, especially acetaminophen overdose and halothane tox-
icity. In the only study to specifically evaluate the etiology of 
the hepatic failure and the prevalence of pancreatitis, acute 
pancreatitis was found to be more common with viral hepatitis 
than in cases of halothane hepatotoxicity. Geokas et al. found 
autopsy evidence of acute pancreatitis in 2 of 33 (6%) patients 
who died of halothane hepatotoxicity and in 7 of 16 (44%) 
patients who died from fulminant viral hepatitis (31). The 
reasons for this relationship between hepatic failure and acute 
pancreatitis are as yet unknown; postulated causes include 
intrapancreatic hemorrhage (33), vascular thrombosis from 
disseminated intravascular coagulation (33), glucocorticoid 
therapy (35)-and, most interestingly, concommitant viral in-
fection of the pancreas (31, 33, 34, 36,-38). Due to the greater 
but not exclusive association of viral hepatitis with acute pan-
creatitis, viral pancreatic infection may be an important mech-
anism responsible for the pancreatitis associated with hepatic 
failure. It should be noted, however, that this certainly is not 
the only cause possible and several other mechanisms are also 
likely. 
Four of the patients described herein with pancreatitis had 
evidence of increased activity of their pretransplant hepatitis 
B virus infection: all four patients had liver histopathologic 
data showing hepatic necrosis and had seroconverted to 
HbeAg+ (3/4) when first studied and/or developed an increase 
in their HbsAg ratio (4/4) over that same period. This increase 
in hepatitis B viral replication is not particularly surprising, as 
increases in hepatitis B viral replication have been shown to 
occur in patients taking chemotherapy (39) and corticosteroids 
(40), as well as in those on immunosuppressive medications 
following renal transplantation (41-42). The fact that hepatitis 
B viral infection ofthe allograft is common (43,44) shows not 
only that immunosuppressive therapy can lead to a state of 
increased viral replication in liver tissue, but also that it can 
result in the dissemmination of hepatitis B virus infection to 
extrahepatic sites. Pancreatic involvement with hepatitis B 
virus has been demonstrated by the finding of hepatitis B viral 
antigens in pure pancreatic juice and pancreatic acinar cells of 
patients with chronic hepatitis B virus infection (45-46). We 
suggest that immunosuppressive stimulation of this pancreatic 
hepatitis B virus infection maybe a likely cause of the pancrea-
titis seen in the patients reported in this investigation. The 
true cause of the pancreatitis may be different for each individ-
ual case and may even be multifactoral in any given case. 
However, the observed association of pancreatitis with recur-
rent acute hepatitis B infection supports hepatitis B pancreatic 
infection as a possible etiologic agent responsibly for of the 
pancreatitis seen in the patients studied. 
In summary, we reported an arithemetically greater preva-
lence of "pancreatitis" and a significantly increased prevalence 
of "hyperamylasemia" after liver transplantation in HbsAg+ 
patients as compared with patients with postnecrotic cirrhosis 
who are HbsAg- and HbcAb or HbsAb+. Moreover, we find a 
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significant association between the development of "recurrent" 
acute hepatitis B infection and the development of postopera-
ti\'e pancreatitis in the patients studied. We suggest that the 
pancreatitis seen in HbsAg+ patients following OL Tx may be 
caused, at least in part, by this immunosuppression and result-
ant accelerated hepatitis B pancreatic infection. 
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